A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
An article from
Dive Brief
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
Published July 21, 2026
General view of the Swiss pharmaceutical and drug company Novartis AG headquarters on April 11, 2025 in Basel, Switzerland.
Novartis says buoyed by new treatments in second quarter
Why Is Novartis Stock Gaining Tuesday? - Novartis (NYSE:NVS)
Novartis Bounds For Buy Point; Why Shares Are On The Rise
Der Pharmakonzern Novartis verjüngt sein Geschäft geschickt
Healthcare Shares Rise — Healthcare Roundup
Novartis supera le attese, BofA conferma buy: i 5 studi clinici di fase III da seguire nel secondo semestre 2026 | MilanoFinanza News
Novartis supera estimativas no 2º trimestre, mas mantém cautela nas estimativas
Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the…
Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as sales for cancer drugs…
Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms…
Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.
Trotz hohen Einbussen beim nicht mehr patentgeschützten Herzmittel Entresto ist Novartis schon wieder auf Wachstumskurs. An der…
Stocks in the healthcare sector posted gains as the broader market recovers.
